Why Spectrum Pharma Is Poised to Outperform

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company Spectrum Pharmaceuticals (NASDAQ: SPPI  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Spectrum and see what CAPS investors are saying about the stock right now.

Spectrum facts

Headquarters (founded)

Henderson, Nev. (1987)

Market Cap

$693.1 million

Industry

Biotechnology

Trailing-12-Month Revenue

$250.6 million

Management

Chairman/CEO Dr. Rajesh Shrotriya (since 2002)
Acting CFO Brett Scott (since 2010)

Return on Equity (average, past 3 years)

11.1%

Cash / Debt

$146.6 million / $75.0 million

Competitors

Biogen Idec
Teva Pharmaceutical

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 454 members who have rated Spectrum believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, Googlespooch, succinctly summed up the Spectrum bull case for our community

The company has a strong pipeline of drugs, keeps getting approvals from the FDA, and has been building strong networks with physicians (prevents generics from taking back that much market share). Also, it has been said that Spectrum has only tapped roughly 50% of the possible physicians to date.

If you want market-topping returns, you need to put together the best portfolio you can. Of course, despite its four-star rating, Spectrum may not be your top choice.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2221513, ~/Articles/ArticleHandler.aspx, 4/19/2014 4:13:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement